BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN. CD47 regulates bone mass and tumor metastasis to bone. Cancer Res 2009;69:3196-204. [PMID: 19276363 DOI: 10.1158/0008-5472.CAN-08-3358] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ. Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo. ACS Chem Biol 2013;8:578-87. [PMID: 23198928 DOI: 10.1021/cb300568r] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
2 Soto-Pantoja DR, Stein EV, Rogers NM, Sharifi-Sanjani M, Isenberg JS, Roberts DD. Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin Ther Targets. 2013;17:89-103. [PMID: 23101472 DOI: 10.1517/14728222.2013.733699] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
3 Bogomiakova ME, Eremeev AV, Lagarkova MA. At Home among Strangers: Is It Possible to Create Hypoimmunogenic Pluripotent Stem Cell Lines? Mol Biol 2019;53:638-52. [DOI: 10.1134/s0026893319050042] [Reference Citation Analysis]
4 Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890-4901. [PMID: 21828138 DOI: 10.1182/blood-2011-02-338020] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 9.0] [Reference Citation Analysis]
5 Dizman N, Buchbinder EI. Cancer Therapy Targeting CD47/SIRPα. Cancers (Basel) 2021;13:6229. [PMID: 34944850 DOI: 10.3390/cancers13246229] [Reference Citation Analysis]
6 Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN. Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J Bone Miner Res 2015;30:106-15. [PMID: 25042340 DOI: 10.1002/jbmr.2308] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
7 Nigro A, Ricciardi L, Salvato I, Sabbatino F, Vitale M, Crescenzi MA, Montico B, Triggiani M, Pepe S, Stellato C, Casolaro V, Dal Col J. Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC. Front Immunol 2019;10:3135. [PMID: 32082304 DOI: 10.3389/fimmu.2019.03135] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Koskinen C, Persson E, Baldock P, Stenberg Å, Boström I, Matozaki T, Oldenborg PA, Lundberg P. Lack of CD47 impairs bone cell differentiation and results in an osteopenic phenotype in vivo due to impaired signal regulatory protein α (SIRPα) signaling. J Biol Chem 2013;288:29333-44. [PMID: 23990469 DOI: 10.1074/jbc.M113.494591] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
9 Maile LA, DeMambro VE, Wai C, Lotinun S, Aday AW, Capps BE, Beamer WG, Rosen CJ, Clemmons DR. An essential role for the association of CD47 to SHPS-1 in skeletal remodeling. J Bone Miner Res. 2011;26:2068-2081. [PMID: 21638321 DOI: 10.1002/jbmr.441] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
10 Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao H, Xu L, Zou Y, Wang W, Yi C, Yin Z, Wang Q. Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor-Glioma Therapy? Front Cell Dev Biol 2021;9:706286. [PMID: 34368156 DOI: 10.3389/fcell.2021.706286] [Reference Citation Analysis]
11 Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2017;165:129-38. [PMID: 28577080 DOI: 10.1007/s10549-017-4318-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Fujiwara T, Ozaki T. Overcoming Therapeutic Resistance of Bone Sarcomas: Overview of the Molecular Mechanisms and Therapeutic Targets for Bone Sarcoma Stem Cells. Stem Cells Int 2016;2016:2603092. [PMID: 28115942 DOI: 10.1155/2016/2603092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
13 Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, Frazier WA. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 2011;30:154-61. [PMID: 21256215 DOI: 10.1016/j.matbio.2010.12.004] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
14 Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res 2012;72:897-907. [PMID: 22186138 DOI: 10.1158/0008-5472.CAN-11-2681] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 5.2] [Reference Citation Analysis]
15 Saltarella I, Desantis V, Melaccio A, Solimando AG, Lamanuzzi A, Ria R, Storlazzi CT, Mariggiò MA, Vacca A, Frassanito MA. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. Cells 2020;9:E167. [PMID: 31936617 DOI: 10.3390/cells9010167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
16 Gauttier V, Pengam S, Durand J, Biteau K, Mary C, Morello A, Néel M, Porto G, Teppaz G, Thepenier V, Danger R, Vince N, Wilhelm E, Girault I, Abes R, Ruiz C, Trilleaud C, Ralph K, Trombetta ES, Garcia A, Vignard V, Martinet B, Glémain A, Bruneau S, Haspot F, Dehmani S, Duplouye P, Miyasaka M, Labarrière N, Laplaud D, Le Bas-Bernardet S, Blanquart C, Catros V, Gouraud PA, Archambeaud I, Aublé H, Metairie S, Mosnier JF, Costantini D, Blancho G, Conchon S, Vanhove B, Poirier N. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance. J Clin Invest 2020;130:6109-23. [PMID: 33074246 DOI: 10.1172/JCI135528] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Isenberg JS, Roberts DD. Thrombospondin-1 in maladaptive aging responses: a concept whose time has come. Am J Physiol Cell Physiol 2020;319:C45-63. [PMID: 32374675 DOI: 10.1152/ajpcell.00089.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Koduru SV, Sun BH, Walker JM, Zhu M, Simpson C, Dhodapkar M, Insogna KL. The contribution of cross-talk between the cell-surface proteins CD36 and CD47-TSP-1 in osteoclast formation and function. J Biol Chem 2018;293:15055-69. [PMID: 30082316 DOI: 10.1074/jbc.RA117.000633] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
19 Chinault SL, Prior JL, Kaltenbronn KM, Penly A, Weilbaecher KN, Piwnica-Worms D, Blumer KJ. Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter. Clin Cancer Res 2012;18:4136-44. [PMID: 22693355 DOI: 10.1158/1078-0432.CCR-12-0642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Chao MP, Weissman IL, Majeti R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012;24:225-32. [PMID: 22310103 DOI: 10.1016/j.coi.2012.01.010] [Cited by in Crossref: 292] [Cited by in F6Publishing: 280] [Article Influence: 29.2] [Reference Citation Analysis]
21 Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest. 2012;122:3579-3592. [PMID: 22996695 DOI: 10.1172/jci38576] [Cited by in Crossref: 63] [Cited by in F6Publishing: 43] [Article Influence: 6.3] [Reference Citation Analysis]
22 Barrett CL, Schwab RB, Jung H, Crain B, Goff DJ, Jamieson CH, Thistlethwaite PA, Harismendy O, Carson DA, Frazer KA. Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One 2013;8:e58714. [PMID: 23527012 DOI: 10.1371/journal.pone.0058714] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
23 Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone 2011;48:54-65. [PMID: 20850578 DOI: 10.1016/j.bone.2010.09.016] [Cited by in Crossref: 112] [Cited by in F6Publishing: 100] [Article Influence: 9.3] [Reference Citation Analysis]
24 Zhang W, Huang Q, Xiao W, Zhao Y, Pi J, Xu H, Zhao H, Xu J, Evans CE, Jin H. Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis. Front Immunol 2020;11:18. [PMID: 32082311 DOI: 10.3389/fimmu.2020.00018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 27.0] [Reference Citation Analysis]
25 Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P, Kaghazian M. Novel molecular insights and new therapeutic strategies in osteosarcoma. Cancer Cell Int 2018;18:158. [PMID: 30349420 DOI: 10.1186/s12935-018-0654-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 9.5] [Reference Citation Analysis]
26 Bastida-Ruiz D, Van Hoesen K, Cohen M. The Dark Side of Cell Fusion. Int J Mol Sci. 2016;17. [PMID: 27136533 DOI: 10.3390/ijms17050638] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
27 Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN. Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model. Nanomedicine 2016;12:201-11. [PMID: 26515754 DOI: 10.1016/j.nano.2015.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
28 Per-Arne O. Role of CD47 and Signal Regulatory Protein Alpha (SIRPα) in Regulating the Clearance of Viable or Aged Blood Cells. Transfus Med Hemother 2012;39:315-20. [PMID: 23801922 DOI: 10.1159/000342537] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
29 Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer. Mol Cancer Ther 2015;14:2473-85. [PMID: 26269605 DOI: 10.1158/1535-7163.MCT-15-0252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
30 Xu JF, Pan XH, Zhang SJ, Zhao C, Qiu BS, Gu HF, Hong JF, Cao L, Chen Y, Xia B, Bi Q, Wang YP. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget 2015;6:23662-70. [PMID: 26093091 DOI: 10.18632/oncotarget.4282] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
31 Hobolt-Pedersen AS, Delaissé JM, Søe K. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif Tissue Int 2014;95:73-82. [PMID: 24862648 DOI: 10.1007/s00223-014-9864-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
32 Oldenborg PA. CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease. ISRN Hematol 2013;2013:614619. [PMID: 23401787 DOI: 10.1155/2013/614619] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 11.6] [Reference Citation Analysis]